236 related articles for article (PubMed ID: 19285025)
1. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
2. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
3. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
[TBL] [Abstract][Full Text] [Related]
4. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
Fan P; Wang J; Santen RJ; Yue W
Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
7. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Schiff R; Massarweh S; Shou J; Osborne CK
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
10. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
14. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
15. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL
Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787
[TBL] [Abstract][Full Text] [Related]
17. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
18. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
[TBL] [Abstract][Full Text] [Related]
20. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.
Santen RJ; Fan P; Zhang Z; Bao Y; Song RX; Yue W
Steroids; 2009 Jul; 74(7):586-94. PubMed ID: 19138696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
